These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34555849)

  • 1. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia.
    Tiong IS; Dillon R; Ivey A; Kuzich JA; Thiagarajah N; Sharplin KM; Kok CH; Tedjaseputra A; Rowland JP; Grove CS; Abro E; Shortt J; Hiwase DK; Bajel A; Potter NE; Smith ML; Hemmaway CJ; Thomas A; Gilkes AF; Russell NH; Wei AH
    Blood Adv; 2021 Dec; 5(23):5107-5111. PubMed ID: 34555849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
    Kapp-Schwoerer S; Weber D; Corbacioglu A; Gaidzik VI; Paschka P; Krönke J; Theis F; Rücker FG; Teleanu MV; Panina E; Jahn N; Herzig J; Kubanek L; Schrade A; Göhring G; Fiedler W; Kindler T; Schroeder T; Mayer KT; Lübbert M; Wattad M; Götze KS; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Krauter J; Bullinger L; Krzykalla J; Benner A; Schlenk RF; Thol F; Heuser M; Ganser A; Döhner H; Döhner K
    Blood; 2020 Dec; 136(26):3041-3050. PubMed ID: 33367545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
    Döhner H; Wei AH; Roboz GJ; Montesinos P; Thol FR; Ravandi F; Dombret H; Porkka K; Sandhu I; Skikne B; See WL; Ugidos M; Risueño A; Chan ET; Thakurta A; Beach CL; Lopes de Menezes D
    Blood; 2022 Oct; 140(15):1674-1685. PubMed ID: 35960871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
    Bataller A; Oñate G; Diaz-Beyá M; Guijarro F; Garrido A; Vives S; Tormo M; Arnan M; Salamero O; Sampol A; Coll R; Vall-Llovera F; Oliver-Caldés A; López-Guerra M; Pratcorona M; Zamora L; Villamon E; Roué G; Blanco A; Nomdedeu JF; Colomer D; Brunet S; Sierra J; Esteve J;
    Br J Haematol; 2020 Oct; 191(1):52-61. PubMed ID: 32510599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
    Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
    J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
    J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
    Lambert J; Lambert J; Nibourel O; Pautas C; Hayette S; Cayuela JM; Terré C; Rousselot P; Dombret H; Chevret S; Preudhomme C; Castaigne S; Renneville A
    Oncotarget; 2014 Aug; 5(15):6280-8. PubMed ID: 25026287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of
    Grob T; Sanders MA; Vonk CM; Kavelaars FG; Rijken M; Hanekamp DW; Gradowska PL; Cloos J; Fløisand Y; van Marwijk Kooy M; Manz MG; Ossenkoppele GJ; Tick LW; Havelange V; Löwenberg B; Jongen-Lavrencic M; Valk PJM
    J Clin Oncol; 2023 Feb; 41(4):756-765. PubMed ID: 36315929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
    Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
    Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
    Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
    Tiong IS; Dillon R; Ivey A; Teh TC; Nguyen P; Cummings N; Taussig DC; Latif AL; Potter NE; Runglall M; Russell NH; Raj K; Schwarer AP; Fong CY; Grigg AP; Wei AH
    Br J Haematol; 2021 Mar; 192(6):1026-1030. PubMed ID: 32458446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.
    Shayegi N; Kramer M; Bornhäuser M; Schaich M; Schetelig J; Platzbecker U; Röllig C; Heiderich C; Landt O; Ehninger G; Thiede C;
    Blood; 2013 Jul; 122(1):83-92. PubMed ID: 23656730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
    Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
    JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.
    Sperr WR; Zach O; Pöll I; Herndlhofer S; Knoebl P; Weltermann A; Streubel B; Jaeger U; Kundi M; Valent P
    Am J Hematol; 2016 Dec; 91(12):1239-1245. PubMed ID: 27643573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
    Pratcorona M; Brunet S; Nomdedéu J; Ribera JM; Tormo M; Duarte R; Escoda L; Guàrdia R; Queipo de Llano MP; Salamero O; Bargay J; Pedro C; Martí JM; Torrebadell M; Díaz-Beyá M; Camós M; Colomer D; Hoyos M; Sierra J; Esteve J;
    Blood; 2013 Apr; 121(14):2734-8. PubMed ID: 23377436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors associated with early treatment response in adults with acute myeloid leukemia].
    Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):869-875. PubMed ID: 29166740
    [No Abstract]   [Full Text] [Related]  

  • 20. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.
    Heidrich K; Thiede C; Schäfer-Eckart K; Schmitz N; Aulitzky WE; Krämer A; Rösler W; Hänel M; Einsele H; Baldus CD; Trappe RU; Stölzel F; Middeke JM; Röllig C; Taube F; Kramer M; Serve H; Berdel WE; Ehninger G; Bornhäuser M; Schetelig J;
    Ann Oncol; 2017 Nov; 28(11):2793-2798. PubMed ID: 28945881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.